OX40: targeted immunotherapy--implications for tempering autoimmunity and enhancing vaccines.

@article{Weinberg2002OX40TI,
  title={OX40: targeted immunotherapy--implications for tempering autoimmunity and enhancing vaccines.},
  author={Andrew D. Weinberg},
  journal={Trends in immunology},
  year={2002},
  volume={23 2},
  pages={102-9}
}
OX40 (CD134), a membrane-bound member of the tumor-necrosis-factor-receptor superfamily, is expressed primarily on activated CD4+ T cells. Recently, several groups have reduced clinical signs of autoimmunity in animal models by blocking the OX40-OX40-ligand interaction or depleting OX40+ T cells. By contrast, engagement of OX40 in the setting of active immunization has potent adjuvant properties, leading to enhanced cytokine production and increased numbers of antigen-specific memory T cells… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 38 extracted citations

Similar Papers

Loading similar papers…